Drug Updates
- Brukinsa Receives Accelerated FDA Approval for Mantle-Cell Lymphoma
- Ziextenzo Third Biosimilar to Neulasta Approved for Febrile Neutropenia
- Tecentriq Approved with Chemotherapy for First-Line Treatment of Metastatic NSCLC without EGFR or ALK Mutations
- FDA Approves Calquence for Adults with CLL or SL
- Zejula Receives FDA Approval for HRD-Positive Advanced Ovarian Cancer
- Teva Will Resume Production of Vincristine in Response to Shortage
- FDA Fast-Tracks Opdivo plus Yervoy Regimen for Treatment of Advanced Liver Cancer
- FDA Grants Accelerated Approval to Brukinsa for Patients with Mantle-Cell Lymphoma
In April 2016, venetoclax (Venclexta; Janssen) became the first BCL-2 inhibitor to be approved by the FDA for relapsed, high-risk chronic lymphocytic leukemia.
Sugammadex (Bridion) injection has been approved for use by the US Food and Drug Administration to reverse the effects of neuromuscular blockade drugs (rocuronium bromide and vecuronium bromide) used during tracheal intubation in adult patients. This injection may help patients recover from these drugs sooner.
Results 1 - 4 of 4
